Study to Determine the Pharmacokinetics of a Single 14C-labeled Intravenous Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose to Postmenopausal Women With Osteopenia or Osteoporosis

NCT00577850 Phase 1 COMPLETED

The primary objective of this study is to compare the urinary excretion of 14C-labeled risedronate and alendronate over 28 days.

Details

Lead sponsor	Warner Chilcott
Phase	Phase 1
Status	COMPLETED
Enrolment	32
Start date	2002-11
Completion	2004-02

Conditions

• Osteopenia
• Osteoporosis

Interventions

• risedronate
• alendronate

Primary outcomes

• compare the urinary excretion of 14C-labeled risedronate and alendronate over 28 days. — 28 days

Countries

United States